Home › Funds › Cormorant Asset Management, LP › DNTH
Cormorant Asset Management, LP position in DNTH
DIANTHUS THERAPEUTICS INC COM · Health Care
Cormorant Asset Management, LP reported holding 750,000 shares of DNTH (DIANTHUS THERAPEUTICS INC COM) in its Q2 2026 13F filing — a position valued at US$73.1M, representing 3.75% of its reported portfolio and ranking #10 among its reported holdings. Cormorant Asset Management, LP has disclosed DNTH holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Cormorant Asset Management, LP's DNTH position evolved
Cormorant Asset Management, LP first disclosed a stake in DNTH in Q1 2026 at 950,000 shares (US$79.7M). Across 2 filings, Cormorant Asset Management, LP increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 750,000 shares valued at US$73.1M — a reduction of -200,000 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 950.00K | $79.72M | New |
| Q2 2026 | 750.00K | $73.11M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About DNTH and 13F data
DNTH (DIANTHUS THERAPEUTICS INC COM) is a Health Care company. 72 other funds we track also report a position in DNTH — the largest reported positions include Fairmount Funds Management LLC (US$247.3M), Avidity Partners Management LP (US$205.1M), Octagon Capital Advisors LP (US$179.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding DNTH
- Fairmount Funds Management LLC 2.54M sh · $247.33M · Q2 2026
- Avidity Partners Management LP 2.10M sh · $205.12M · Q2 2026
- Octagon Capital Advisors LP 1.84M sh · $179.53M · Q2 2026
- TCG Crossover Management, LLC 1.68M sh · $163.44M · Q2 2026
- FRED ALGER MANAGEMENT, LLC 1.30M sh · $126.97M · Q2 2026
- Venrock Adviser, LLC 1.18M sh · $115.03M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 1.13M sh · $109.70M · Q2 2026
- BAKER BROS. ADVISORS LP 852.16K sh · $83.07M · Q2 2026
- Logos Global Management LP 800.00K sh · $77.98M · Q2 2026
- BRAIDWELL LP 594.56K sh · $57.96M · Q2 2026
- MPM BioImpact LLC 420.00K sh · $40.94M · Q2 2026
- Affinity Asset Advisors, LLC 400.00K sh · $38.99M · Q2 2026
More on Cormorant Asset Management, LP
FAQ
How long has Cormorant Asset Management, LP held DNTH?
Cormorant Asset Management, LP has disclosed DNTH holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is Cormorant Asset Management, LP's current position in DNTH?
As of Q2 2026, Cormorant Asset Management, LP holds 750.00K shares of DNTH (DIANTHUS THERAPEUTICS INC COM), valued at $73.11M, representing 3.75% of its reported portfolio and ranking #10.
Has Cormorant Asset Management, LP been buying or selling DNTH?
In the latest 13F filing (Q2 2026), Cormorant Asset Management, LP reduced its position in DNTH.
Which other funds hold DNTH?
Other major institutional holders of DNTH include Fairmount Funds Management LLC, Avidity Partners Management LP, Octagon Capital Advisors LP, among 72 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.